entertainment -WSS

entertainment

author：leisure time 2025-10-01 17:56:35 - browse：74

Marc Tessier Lavigne (center) retracted two Science papers on the day his resignation as Stanford president takes effect. Mattarella in San Francisco

After an expansive investigation found manipulated data and other issues with papers co-authored by Stanford’s now ex-president Marc Tessier-Lavigne, the prominent neuroscientist on Thursday retracted two studies published in the journal Science in 2001 — over the objection of a former postdoctoral researcher who played a leading role in both projects.

The retractions come the same day that Tessier-Lavigne’s resignation as Stanford president takes effect. His departure was prompted by a 95-page report released by a special committee of the university’s Board of Trustees, which recruited outside scientists and a former federal judge to investigate a dozen papers Tessier-Lavigne co-authored between 1999 and 2009, years before becoming the university’s leader.

The panel concluded that he did not personally engage in scientific misconduct, but it uncovered manipulated data in some studies Tessier-Lavigne had supervised and found that he took insufficient steps to “decisively and forthrightly” correct these studies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： FTC loses bid to block Novant's North Carolina hospital merger

WSS

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

For pregnant people, addiction treatment shouldn't mean a call to child protective services

FDA approves Moderna’s RSV vaccine, its second licensed product

Addiction experts warn against a second 'war on drugs'

Arc Institute generative AI designs new CRISPR systems

STAT wants to know your pick for a great summer read or listen

entertainment

entertainment

leisure time

Alkermes shareholders re

Case highlights the risks of experimental stem cell therapy

In age of alternative facts, a scholarly course on calling out crap

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Anesthesiologist group: stop taking Ozempic before surgery

With measles on the rise, a personal story of a devastating disease

In Memoriam: Notable people who died in 2023

Medicare Advantage's lean provider networks lead CMS complaints

The high cost of giving birth even with insurance

The most pressing bird flu mysteries scientists want answered

hotspot

Case highlights the risks of experimental stem cell therapy

Readout LOUD podcast: Live from STAT Breakthrough Summit West

A new initiative will help leaders fight the next pandemic

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

entertainment

hotspot

focus

entertainment